IPSC has 36-month beta value of 1.37. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IPSC is 32.54M, and currently, short sellers hold a 10.07% ratio of that float. The average trading volume of IPSC on October 04, 2024 was 324.54K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IPSC) stock’s latest price update
Century Therapeutics Inc (NASDAQ: IPSC)’s stock price has dropped by -6.21 in relation to previous closing price of 1.61. Nevertheless, the company has seen a loss of -1.31% in its stock price over the last five trading days. globenewswire.com reported 2024-09-26 that – Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer –
IPSC’s Market Performance
IPSC’s stock has fallen by -1.31% in the past week, with a monthly drop of -5.03% and a quarterly drop of -32.59%. The volatility ratio for the week is 9.66% while the volatility levels for the last 30 days are 9.43% for Century Therapeutics Inc The simple moving average for the past 20 days is -4.72% for IPSC’s stock, with a -50.75% simple moving average for the past 200 days.
Analysts’ Opinion of IPSC
Many brokerage firms have already submitted their reports for IPSC stocks, with Rodman & Renshaw repeating the rating for IPSC by listing it as a “Buy.” The predicted price for IPSC in the upcoming period, according to Rodman & Renshaw is $6 based on the research report published on August 08, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see IPSC reach a price target of $5, previously predicting the price at $28. The rating they have provided for IPSC stocks is “Neutral” according to the report published on August 28th, 2023.
Chardan Capital Markets gave a rating of “Buy” to IPSC, setting the target price at $19 in the report published on December 27th of the previous year.
IPSC Trading at -13.99% from the 50-Day Moving Average
After a stumble in the market that brought IPSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.60% of loss for the given period.
Volatility was left at 9.43%, however, over the last 30 days, the volatility rate increased by 9.66%, as shares surge +4.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.55% lower at present.
During the last 5 trading sessions, IPSC fell by -1.31%, which changed the moving average for the period of 200-days by -48.11% in comparison to the 20-day moving average, which settled at $1.5883. In addition, Century Therapeutics Inc saw -54.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IPSC starting from Quimi Daphne, who purchase 5,000 shares at the price of $1.53 back on Sep 12 ’24. After this action, Quimi Daphne now owns 5,000 shares of Century Therapeutics Inc, valued at $7,657 using the latest closing price.
Farid Adrienne, the Chief Operations Officer of Century Therapeutics Inc, sale 1,073 shares at $1.83 during a trade that took place back on Aug 05 ’24, which means that Farid Adrienne is holding 136,163 shares at $1,960 based on the most recent closing price.
Stock Fundamentals for IPSC
Current profitability levels for the company are sitting at:
- -65.18 for the present operating margin
- -4.89 for the gross margin
The net margin for Century Therapeutics Inc stands at -64.34. The total capital return value is set at -0.33. Equity return is now at value -55.95, with -31.52 for asset returns.
Based on Century Therapeutics Inc (IPSC), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is 123.23.
Currently, EBITDA for the company is -112.14 million with net debt to EBITDA at -0.13. When we switch over and look at the enterprise to sales, we see a ratio of 69.95. The receivables turnover for the company is 1.16for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.62.
Conclusion
To put it simply, Century Therapeutics Inc (IPSC) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
